Patents by Inventor Thayer White
Thayer White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250075001Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: July 9, 2024Publication date: March 6, 2025Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Patent number: 12201748Abstract: Compositions and blends of biopolymers and bio-acceptable polymers are described, along with the use of benign solvent systems to prepare biocompatible scaffolds and surgically implantable devices for use in supporting and facilitating the repair of soft tissue injuries.Type: GrantFiled: December 16, 2021Date of Patent: January 21, 2025Assignee: Embody, Inc.Inventors: Michael P. Francis, Yas Maghdouri-White, Hilary Wriggers, Nardos Sori, Stella Petrova, Seth Polk, Nicholas Thayer
-
Patent number: 12065504Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: GrantFiled: September 29, 2021Date of Patent: August 20, 2024Assignee: GO Therapeutics, Inc.Inventor: Thayer White
-
Publication number: 20220089772Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: September 29, 2021Publication date: March 24, 2022Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Patent number: 11161911Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: GrantFiled: October 23, 2018Date of Patent: November 2, 2021Assignee: GO Therapeutics, Inc.Inventor: Thayer White
-
Publication number: 20210269552Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: June 28, 2019Publication date: September 2, 2021Applicant: GO Therapeutics, Inc.Inventors: Thayer White, Hans H. WANDALL
-
Publication number: 20190119400Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.Type: ApplicationFiled: October 23, 2018Publication date: April 25, 2019Applicant: GO Therapeutics, Inc.Inventor: Thayer WHITE
-
Publication number: 20070072856Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.Type: ApplicationFiled: November 16, 2006Publication date: March 29, 2007Applicant: Cell Therapeutics, Inc.Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung
-
Publication number: 20060035896Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPMT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.Type: ApplicationFiled: September 12, 2005Publication date: February 16, 2006Applicant: Cell Therapeutics, Inc.Inventors: Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung, Baoqing Gong, John Tulinsky
-
Patent number: 6331254Abstract: Methods which employ thin layer chromatography for separating and detecting hydrophobic target molecules are particularly useful in separating biologically relevant lipids. By utilizing non-destructive detection techniques, these methods also can be adapted to further quantification or structural analysis.Type: GrantFiled: December 17, 1999Date of Patent: December 18, 2001Assignee: Cell Therapeutics, Inc.Inventors: Thayer White, Edward Nudelman
-
Patent number: 5326857Abstract: The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.Type: GrantFiled: August 29, 1991Date of Patent: July 5, 1994Assignee: The Biomembrane InstituteInventors: Fumi-ichiro Yamamoto, Thayer White, Sen-itiroh Hakomori, Henrik Clausen
-
Patent number: 5068191Abstract: The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.Type: GrantFiled: August 31, 1989Date of Patent: November 26, 1991Assignee: The Biomembrane InstituteInventors: Henrik Clausen, Fumi-ichiro Yamamoto, Thayer White, Sen-itiroh Hakomori
